罕见病医疗保障机制研究:以血友病为例

李常印, 殷玉如

中国医疗保险 ›› 2023, Vol. 0 ›› Issue (7) : 104-110.

中国医疗保险 ›› 2023, Vol. 0 ›› Issue (7) : 104-110. DOI: 10.19546/j.issn.1674-3830.2023.7.014
医药经纬

罕见病医疗保障机制研究:以血友病为例

  • 李常印1, 殷玉如2
作者信息 +

Study on Medical Security Mechanism of Rare Diseases: A Case Study of Hemophilia

Author information +
文章历史 +

摘要

罕见病医疗保障机制的完善是中国特色多层次医疗保障体系高质量发展的重要组成部分。本文以血友病患者及其医疗保障情况作为研究对象,通过实地调查、个案访谈等研究方法,探讨罕见病患者治疗情况、用药方式、医疗机构选择和基本医保参保状况等。同时,综合分析我国血友病患者的医疗保障政策,包括国家医保药品目录准入情况、城乡居民大病保险制度、重特大疾病医疗保险和救助制度,以及地方血友病医疗保障政策等。基于这些分析,本文提出支持罕见病用药创新发展、完善医保药品目录准入机制、建立健全罕见病保障体系,以及加强罕见病诊疗能力建设的政策建议,以此推动罕见病医疗保障机制的完善。

Abstract

The improvement of the medical security mechanism for rare diseases is an important part of the high-quality development of a multi-level medical security system with Chinese characteristics. In this paper, hemophilia patients and their medical security were the research objects. Through field investigation, case interview and other research methods, the paper discussed the treatments, medication methods, medical institution selection and basic medical insurance participation of rare disease patients. At the same time, it comprehensively analyzed the medical security policies of hemophilia patients in China, including the access to the national medical insurance drug list, the serious illness insurance system for urban and rural residents, the medical insurance and assistance system for major and very serious diseases, and the local hemophilia medical security policies. Based on these analyses, policy suggestions were put forward to support the innovation and development of rare disease drugs, improve the access mechanism of medical insurance drug catalogue, establish and improve a sound rare disease security system, and strengthen the construction of diagnosis and treatment capacity, so as to promote the improvement of the rare disease medical security mechanism.

关键词

罕见病 / 医疗保障 / 血友病

Key words

rare disease / medical security / hemophilia

引用本文

导出引用
李常印, 殷玉如. 罕见病医疗保障机制研究:以血友病为例[J]. 中国医疗保险. 2023, 0(7): 104-110 https://doi.org/10.19546/j.issn.1674-3830.2023.7.014
Study on Medical Security Mechanism of Rare Diseases: A Case Study of Hemophilia[J]. China Health Insurance. 2023, 0(7): 104-110 https://doi.org/10.19546/j.issn.1674-3830.2023.7.014
中图分类号: F840.684C913.7   

参考文献

[1] 张晓星,周婷婷,潘杰.国内外罕见病用药保障模式的评述[J].中国卫生政策研究,2020,13(11):18-23.
[2] The Ryan Foundation.Facts about rare diseases[EB/OL].(2017-09-05)[2022-01-06].https://ryanfoundation.org/home.
[3] BLIN O, LEFEBVRE MN, RASCOL O, et al.Orphan drug clinical development[J].2020,75(2):141-147.
[4] 国家卫生健康委,科学技术部,工业和信息化部,等.关于公布第一批罕见病目录的通知:国卫医发〔2018〕10号[EB/OL].(2018-06-08)[2023-06-20].http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.
[5] 逯军,潘翔.浅谈我国罕见病的研究现状与未来[J].中国热带医学,2023,23(02):109-114.
[6] 晟斯生物重组八因子血友病病友深度访谈调查报告[R].晟斯生物重组八因子血友病病友深度访谈调查报告[R].2022.

Accesses

Citation

Detail

段落导航
相关文章

/